#United States #New Orleans #ClaimsFiler #deramiocel #Capricor Therapeutics

Capricor Therapeutics Investor Alert: Your Call to Action

In light of recent developments regarding Capricor Therapeutics, Inc. (NASDAQ: CAPR), a significant opportunity has emerged for investors who faced substantial financial losses. ClaimsFiler, a free service dedicated to helping shareholders, has publicly announced a deadline of September 28, 2026 for filing lead plaintiff applications in a class action lawsuit against the company. This action is set against the backdrop of troubling claims surrounding financial mismanagement and a deceptive disclosure of critical information during the designated class period, which spans from December 17, 2025, to July 26, 2026.

Key Facts About the Lawsuit

The basis of the lawsuit arises from allegations that Capricor and its executives failed to reveal material information to investors, violating federal securities laws. In a significant turn of events, the U.S. Food and Drug Administration (FDA) issued briefing documents on July 27, 2026, prior to an important advisory committee meeting scheduled for July 29. The documents revealed that Capricor had altered the pre-specified statistical analysis plan related to Deramiocel, their leading product candidate.

These changes, which reversed the statistical assessment approach without adequate scientific justification, led to the FDA's stance that the company's results were compromised. The regulatory body highlighted that the changes added unnecessary complexity to the data interpretation, ultimately adversely affecting the perceived efficacy of Deramiocel. As a result of these unsettling findings, Capricor’s stock plummeted by 64%, closing at $7.00 per share, highlighting the detrimental impact of the mishandling of information on investor confidence.

The Implications for Investors

For those who invested during the specified period and incurred losses exceeding $100,000, now is the time to consider your legal options. ClaimsFiler has positioned itself as an invaluable resource for shareholders, offering essential information and support throughout the recovery process.

To access the necessary legal resources, investors can navigate to ClaimsFiler's dedicated web page or connect with the legal experts at Kahn Swick & Foti, LLC, who can provide complimentary case evaluations and support in pursuing claims. The case is officially recognized as Nkamga v. Capricor Therapeutics, Inc., et al., No. 326-cv-04385 in the United States District Court for the Southern District of California.

Your Next Steps

Investors are encouraged to stay proactive. The implications of this lawsuit could extend beyond mere monetary compensation; it speaks to the fundamental right of shareholders to transparency and honesty from the companies in which they invest.

• - Visit ClaimsFiler to learn more about the potential to reclaim losses.
• - Call toll-free at 833-538-3604 to consult with legal professionals.
• - Ensure your participation by meeting the deadline on September 28, 2026.

This class action is not just another legal battle; it’s a fight for accountability in the business practices of publicly traded companies like Capricor Therapeutics. Investors must act swiftly to protect their interests and pursue justice.

In conclusion, as the financial landscape continues to evolve, staying informed and making timely decisions is crucial for all stakeholders in the market. Don’t miss out on this pivotal moment; act now to secure your position.